> 资讯
February 21, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2024.
Philips’ Annual Report 2024 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2025. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.
Philips filed the Annual Report 2024 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).
The Annual Report 2024 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.
For further information, please contact:
Elco van Groningen
Philips Global External Relations
Tel.: +31 68103 9584
E-mail: elco.van.groningen@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18.0 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
相关推荐
- Philips publishes its Annual Report 2024
- Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
- 聚焦热门话题,150+采购团,BTE 2025助企高效对接
- 糖立康创始人向梅英:科技赋能,开启糖尿病管理新篇章
- PCHi2025圆满成功!博溪检测科技创新领航化妆品CRO服务未来
- 糖立康创始人向梅英引领健康革命:全链条管理体系破解糖尿病难题
- 糖立康创始人向梅英:引领糖尿病患者走向科学逆糖之路
- 平安养老险福建分公司:“橙”心守护平安年,平安养老险开展新春系列活动
- 「AI in Action」主题招聘会 首度聚焦人工智能 提供逾千个就业机会 吸纳顶尖科技人才应对行业需求
- Witsbb健敏思携手老爸评测为安全消费把关,品质认证驱动消费决策升级
- 搜索
-
- 02-24Philips publishes its Annual Report 2024
- 02-24Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
- 02-24聚焦热门话题,150+采购团,BTE 2025助企高效对接
- 02-24糖立康创始人向梅英:科技赋能,开启糖尿病管理新篇章
- 02-24PCHi2025圆满成功!博溪检测科技创新领航化妆品CRO服务未来
- 02-24糖立康创始人向梅英引领健康革命:全链条管理体系破解糖尿病难题
- 02-24糖立康创始人向梅英:引领糖尿病患者走向科学逆糖之路
- 02-24平安养老险福建分公司:“橙”心守护平安年,平安养老险开展新春系列活动
- 02-24「AI in Action」主题招聘会 首度聚焦人工智能 提供逾千个就业机会 吸纳顶尖科技人才应对行业需求
- 02-24Witsbb健敏思携手老爸评测为安全消费把关,品质认证驱动消费决策升级
- 标签列表